Breast Cancer Cell 500X500

City of Hope is accelerating the development of treatment options for patients with breast cancer who have challenging tumors and poor prognosis with a phase 1 clinical trial that is enrolling patients with refractory HER2-positive breast cancer with brain metastases to test the safety and effectiveness of CAR T cell therapy.


brain tumor

City of Hope has opened a first-in-human clinical trial for patients with recurrent glioblastoma – the trial is the first to combine City of Hope’s unique CAR T cell therapy with immune checkpoint inhibitors.


News Image

The trial, which received a $4.1 million in grants from the National Institutes of Health and Gateway for Cancer Research, combines City of Hope’s unique CAR T cell therapy with immune checkpoint inhibitors

Larry Kwak

City of Hope’s research on the new CAR T therapy, published in Science Translational Medicine, offers hope for patients who have relapsed after commercially available CD19 immunotherapy treatments.


News Image

City of Hope’s research on the new CAR T, published in Science Translational Medicine, offers hope for patients who have relapsed after commercially available CD19 immunotherapy treatments.

Nathwani-Nitya

Despite the availability of many emerging treatments for multiple myeloma, it remains an incurable cancer. As a pioneer in advancing personalized medicine and commitment to improved patient outcomes, City of Hope experts have joined efforts for a unique clinical trial.


News Image

The trial is one of the first CAR T cell trials nationwide to enroll prostate cancer patients.

colorectal cancer screening

People with colon and rectal tumors prone to “immune overdrive” don’t do well if they concurrently have an immune-suppressive tumor microenvironment, City of Hope researchers say.


News Image

People with colon and rectal tumors prone to “immune overdrive” don’t do well if they concurrently have an immune-suppressive tumor microenvironment, City of Hope researchers say.

HPV cells

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.


Breakthroughs - prostate cancer clinical trial

In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.


Saul Priceman | City of Hope

Saul Priceman, Ph.D., and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.


News Image

Saul Priceman, Ph.D., City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received an award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

News Image

City of Hope researchers found that “turning off” the BCL6 protein and using the small molecule ABT-199 eliminated drug resistance in mouse models that had a subtype of B cell acute lymphoblastic leukemia.

News Image

City of Hope is the first institution in the United States to open an immunotherapy clinical trial for liver cancer that, if successful, eventually could transform treatment of the usually fatal disease into an outpatient procedure.

Caitlin Buchanon Small | City of Hope

Diagnosed with a rare, fast-growing blood cancer and ineligible for a lifesaving stem cell transplant after failing chemotherapy, treatment with a breakthrough CAR T drug called Yescarta was Caitlin Buchanan's best hope for survival.


Nadia Carlesso, M.D. - Profile Photo

Inspiration came early to Nadia Carlesso, M.D., Ph.D., associate director of basic research in the Gehr Family Center for Leukemia Research at City of Hope.


Radiotherapy for Breast Cancer at City of Hope

A special blood test may one day predict if a newly diagnosed breast cancer patient will likely relapse years later, a City of Hope study suggests.


News Image

A special blood test may one day predict if a newly diagnosed breast cancer patient will likely relapse years later, a City of Hope study suggests.

Warner-Susanne

At City of Hope since 2015, Susanne Warner, M.D., regularly draws notice and praise for her surgical skills, her research chops and especially her Texas-sized optimism.


Tyler Routh | City of Hope

Tyler Routh is one of 13 leukemia patients who had a remarkable recovery after participating in Dr. Samer Khaled’s CAR T trial.


li-daneng-300x300

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly impossible-to-treat cancer into a disease that can be corralled into remission.


Ammar Chaudhry

The dynamic young founder and director of City of Hope’s Precision Imaging Lab, Ammar Chaudhry, M.D., is one of the first recipients of the new ORIEN NOVA Award. The $1 million grant will fund research for his breakthrough approach to cancer imaging and diagnosis.


Ammar Chaudhry

The dynamic young founder and director of City of Hope’s Precision Imaging Lab, Ammar Chaudhry, M.D., is one of the first recipients of the new ORIEN NOVA Award. The $1 million grant will fund research for his breakthrough approach to cancer imaging and diagnosis.


News Image

Study results will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.